Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0428
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus ; volume:62 ; number:3 ; day:28 ; month:12 ; year:2018 ; pages:373-386 ; date:3.2019
Diabetologia ; 62, Heft 3 (28.12.2018), 373-386, 3.2019
- Creator
-
Jain, Meena
Carlson, Glenn
Cook, William
Morrow, Linda
Petrone, Marcella
White, Nicholas E.
Wang, Tao
Naylor, Jacqueline
Ambery, Philip
Lee, Charles
Hirshberg, Boaz
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00125-018-4789-6
- URN
-
urn:nbn:de:101:1-2019031523540063733183
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jain, Meena
- Carlson, Glenn
- Cook, William
- Morrow, Linda
- Petrone, Marcella
- White, Nicholas E.
- Wang, Tao
- Naylor, Jacqueline
- Ambery, Philip
- Lee, Charles
- Hirshberg, Boaz
- SpringerLink (Online service)
Other Objects (12)
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Gene Therapy Targeting PCSK9
GLP (Grünleitplan)
Response-adaptive dose-finding under model uncertainty
Optimal dose‐finding for efficacy–safety models
Synthesis of a PCSK9 Inhibitor
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
Revisiting dose-finding of monoclonal antibodies in migraine
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Gene Therapy Targeting PCSK9
GLP (Grünleitplan)
Response-adaptive dose-finding under model uncertainty
Optimal dose‐finding for efficacy–safety models
Synthesis of a PCSK9 Inhibitor
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
Revisiting dose-finding of monoclonal antibodies in migraine
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Gene Therapy Targeting PCSK9
GLP (Grünleitplan)
Response-adaptive dose-finding under model uncertainty
Optimal dose‐finding for efficacy–safety models
Synthesis of a PCSK9 Inhibitor
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction